MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Please find attached daily report pursuant to Regulation 18 of Buyback Regulations25-07-2022
25-07-2022
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Please find attached daily report pursuant to Regulation 18 of Buyback Regulations21-07-2022
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Marksans Pharma Limited announces US FDA approval for Pregabalin Capsules, 25 mg, 50 mg,75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg ANDA.21-07-2022
MARKSANS PHARMA LTD. - 524404 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Harshavardhan PanigrahiDesignation :- Company Secretary and Compliance Officer19-07-2022
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Please find attached daily report pursuant to Regulation 18 of Buyback Regulations18-07-2022
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Please find attached daily report pursuant to Regulation 18 of Buyback Regulations15-07-2022
MARKSANS PHARMA LTD. - 524404 - Intimation Of Date Of Commencement Of Buyback
Please find attached the intimation of commencement of Buyback of Marksans Pharma Limited.15-07-2022
MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2022.13-07-2022
MARKSANS PHARMA LTD. - 524404 - Buyback Offer
Sundae Capital Advisors Pvt Ltd ("Manager to the Buy-Back Offer) has submitted to BSE a copy of Public Announcement for the attention of Equity Shareholders / Beneficial owners of Equity Shares of Marksans Pharma Ltd ("the Company") for the Buyback of Equity Shares from the Open Market through Stock Exchanges under the Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018, as amended.12-07-2022
MARKSANS PHARMA LTD. - 524404 - Certified Copy Of The Resolution Passed By The Board Of Directors Of Marksans Pharma Limited Approving The Buyback Of Equity Shares Of The Company
In furtherance to the outcome letter dated July 08, 2022, and pursuant to the Regulation 5(vii) of the SEBI (Buy-back of Securities) Regulations, 2018, enclosed herewith is the certified true copy of the resolution passed by the board of directors at its meeting held on July 08, 2022, approving the buyback of equity shares of the Company.12-07-2022